SCHEMBL8282776

SCHEMBL8282776

CCc1nc(-c2ccc(F)c(N)c2)no1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 2/20 0.48
▸ ACACA Q13085 2/20 0.48
▸ NPC1 O15118 5/20 0.48
▸ RAB9A P51151 5/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ HTT P42858 2/20 0.48
▸ NOTUM Q6P988 2/20 0.44
▸ LMNA P02545 5/20 0.44
▸ HSD17B10 Q99714 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ ESR2 Q92731 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ MAPK1 P28482 2/20 0.41
▸ S1PR1 P21453 1/20 0.41
▸ S1PR3 Q99500 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12021873 0.85 MAPK1 (0.56) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL8415707 0.84 FFAR1 (0.53) ACACBACACANPC1RAB9ASMN1; SMN2
SCHEMBL12021945 0.82 ACACB (0.48) ACACBACACANPC1RAB9ASMN1; SMN2
SCHEMBL14741890 0.80 RAB9A (0.44) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL14741570 0.80 TSHR (0.50) NPC1RAB9ASMN1; SMN2LMNAMAPT
SCHEMBL8282433 0.80 L3MBTL1 (0.57) NPC1RAB9ASMN1; SMN2LMNAHSD17B10
SCHEMBL8226480 0.80 ACACB (0.46) ACACBACACANPC1RAB9ASMN1; SMN2
SCHEMBL14757481 0.79 MAPK1 (0.46) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL26232436 0.78 NPC1 (0.73) ACACBACACANPC1RAB9ASMN1; SMN2
SCHEMBL5311162 0.78 ACACB (0.59) ACACBACACANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934227-B1 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS SCHERING CORP (US) 2011-12-21 — — EP disclosed
EP-1745047-B1 PYRAZOLO[4,3-E]-1,2,4-TRIAZOLO[1,5-C]PYRIMIDINE ADENOSINE-A2A- RECEPTOR ANTAGONISTS SCHERING CORP (US) 2010-03-24 — — EP disclosed
WO-2007035542-A1 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2007-03-29 — — WO disclosed
WO-2005103055-A1 PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2005-11-03 — — WO disclosed
Send feedback